We read with interest the article focusing on use of immunohistochemical markers for
classification of hormone receptor-positive breast cancer into luminal A and luminal
B subtypes, published in your esteemed journal.
1
The authors have studied the utility of immunohistochemical markers (estrogen receptor,
progesterone receptor, human epidermal growth factor receptor 2 [HER2], and Ki67)
with fluorescence in situ hybridization testing for equivocal HER2 expression on immunohistochemistry
(IHC). The classification between luminal A and luminal B subtypes has been based
on St Gallen guidelines.
2
The authors have also compared the hot spot and average methods for the assessment
for Ki67 labeling index. They found that only 6% of the cases were differently classified
between the hot spot and average methods, and they have used the hot spot method for
final classification in their study. We would like to complement the authors for this
study, which is probably the largest study from an Indian center focusing of this
aspect of breast cancer management. There are some comments that we wanted to share
with the authors and the readers.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Breast CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Identification of luminal subtypes of breast carcinoma using surrogate immunohistochemical markers and ascertaining their prognostic relevance.Clin Breast Cancer. 2020; 20: 382-389
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer, 2013.Ann Oncol. 2013; 24: 2206-2223
- A comparison of Ki-67 counting methods in luminal breast cancer: the average method vs. the hot spot method.PLoS One. 2017; 12: e0172031
- Prognostic potential of automated Ki67 evaluation in breast cancer: different hot spot definitions versus true global score.Breast Cancer Res Treat. 2020; 183: 161-175
Article info
Publication history
Published online: September 27, 2020
Accepted:
July 29,
2020
Received:
July 27,
2020
Identification
Copyright
© 2020 Elsevier Inc. All rights reserved.
